Michael Ryskin
Stock Analyst at B of A Securities
(2.17)
# 3,186
Out of 4,829 analysts
34
Total ratings
50%
Success rate
9.11%
Average return
Main Sectors:
Stocks Rated by Michael Ryskin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRVI Maravai LifeSciences Holdings | Maintains: Buy | $9 → $8 | $2.12 | +277.36% | 3 | Mar 3, 2025 | |
| TEM Tempus AI | Maintains: Neutral | $54 → $60 | $62.69 | -4.29% | 4 | Mar 3, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $475 → $535 | $509.53 | +5.00% | 2 | Feb 4, 2025 | |
| ALGN Align Technology | Maintains: Underperform | $200 → $206 | $189.00 | +8.99% | 6 | Dec 13, 2024 | |
| GH Guardant Health | Maintains: Buy | $28 → $40 | $41.66 | -3.98% | 1 | Jul 18, 2024 | |
| ALIT Alight | Maintains: Buy | $10 → $9.5 | $5.79 | +64.08% | 1 | Jun 25, 2024 | |
| CERT Certara | Maintains: Buy | $27 → $24 | $12.13 | +97.86% | 2 | Aug 15, 2023 | |
| AVTR Avantor | Maintains: Buy | $27 → $24 | $13.00 | +84.62% | 2 | Jul 31, 2023 | |
| ZTS Zoetis | Maintains: Buy | $225 → $180 | $161.92 | +11.17% | 7 | Nov 4, 2022 | |
| RXRX Recursion Pharmaceuticals | Downgrades: Neutral | n/a | $4.64 | - | 2 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $52 | $24.17 | +115.14% | 2 | Nov 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $17 → $10 | $2.93 | +241.30% | 2 | Nov 10, 2021 |
Maravai LifeSciences Holdings
Mar 3, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.12
Upside: +277.36%
Tempus AI
Mar 3, 2025
Maintains: Neutral
Price Target: $54 → $60
Current: $62.69
Upside: -4.29%
IDEXX Laboratories
Feb 4, 2025
Maintains: Neutral
Price Target: $475 → $535
Current: $509.53
Upside: +5.00%
Align Technology
Dec 13, 2024
Maintains: Underperform
Price Target: $200 → $206
Current: $189.00
Upside: +8.99%
Guardant Health
Jul 18, 2024
Maintains: Buy
Price Target: $28 → $40
Current: $41.66
Upside: -3.98%
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10 → $9.5
Current: $5.79
Upside: +64.08%
Certara
Aug 15, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $12.13
Upside: +97.86%
Avantor
Jul 31, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $13.00
Upside: +84.62%
Zoetis
Nov 4, 2022
Maintains: Buy
Price Target: $225 → $180
Current: $161.92
Upside: +11.17%
Recursion Pharmaceuticals
Apr 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $4.64
Upside: -
Nov 11, 2021
Downgrades: Neutral
Price Target: $80 → $52
Current: $24.17
Upside: +115.14%
Nov 10, 2021
Downgrades: Underperform
Price Target: $17 → $10
Current: $2.93
Upside: +241.30%